Table 2.
Patient characteristics: metastatic disease
| Characteristic | n (%) |
| Menopausal status | |
| Premenopausal | 5 (31) |
| Postmenopausal | 9 (56) |
| Unknown | 2 (13) |
| Disease sites | |
| 1 | 1 (6) |
| 2 | 7 (44) |
| 3 | 6 (38) |
| ≥ 4 | 2 (12) |
| Predominantly visceral disease | |
| Yes | 3 (19) |
| No | 13 (81) |
| Line of treatment | |
| 0 | 3 (19) |
| 1 | 6 (37) |
| 2 | 3 (19) |
| ≥- 3 | 4 (25) |
| ER/PR tumor status | |
| Positive | 11 (69) |
| Negative | 5 (31) |
| HER2 tumor status | |
| Positivea | 5 (31) |
| Negative | 11(69) |
| EGFR tumor status | |
| Positive | 1(6) |
| Negative | 9 (56) |
| Unknown | 6 (38) |
aA score +3 or fluorescence in situ hybridization positive. EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER, human epidermal growth factor receptor; PR, progesterone receptor.